Stockreport

ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF This compares to the stock's 8% gain over the past four weeks. Last week, the company announced the dosing of the first patient in a phase I study evaluating its CAR-N [Read more]